within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07A_IntestinalAntiinfectives.A07AA07_AmphotericinB;

model AmphotericinB
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.1500000000000003e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.00041999999999999996,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00032,
    k12 = 2.4500000000000003e-05,
    k21 = 2.4500000000000003e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>AmphotericinB</td></tr><tr><td>ATC code:</td><td>A07AA07</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.42</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.0027</td><td>L/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Amphotericin B is a polyene antifungal medication used primarily for the treatment of severe systemic fungal infections, including cryptococcal meningitis, aspergillosis, histoplasmosis, and candidiasis. It is considered a drug of last resort due to its nephrotoxicity but remains in use, particularly in immunocompromised patients. Amphotericin B is approved for clinical use and is available in both deoxycholate and lipid formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with systemic fungal infections receiving intravenous amphotericin B deoxycholate.</p><h4>References</h4><ol><li><p>Groll, AH, et al., &amp; Brüggemann, RJM (2019). Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 68(Suppl 4) S260–S274. DOI:<a href=\"https://doi.org/10.1093/cid/ciz076\">10.1093/cid/ciz076</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31222253/\">https://pubmed.ncbi.nlm.nih.gov/31222253</a></p></li><li><p>Würthwein, G, et al., &amp; Walsh, TJ (2005). Population pharmacokinetics of amphotericin B lipid complex in neonates. <i>Antimicrobial agents and chemotherapy</i> 49(12) 5092–5098. DOI:<a href=\"https://doi.org/10.1128/AAC.49.12.5092-5098.2005\">10.1128/AAC.49.12.5092-5098.2005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16304177/\">https://pubmed.ncbi.nlm.nih.gov/16304177</a></p></li><li><p>Nath, CE, et al., &amp; Earl, JW (2001). Population pharmacokinetics of amphotericin B in children with malignant diseases. <i>British journal of clinical pharmacology</i> 52(6) 671–680. DOI:<a href=\"https://doi.org/10.1046/j.0306-5251.2001.01496.x\">10.1046/j.0306-5251.2001.01496.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11736878/\">https://pubmed.ncbi.nlm.nih.gov/11736878</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A07AA07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end AmphotericinB;
